Experts question Amarin's early touting of Vescepa data ahead of detailed results

At the end of September, Amarin teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease. The claim was astounding: a 25% relative risk reduction for deaths related to heart attacks, strokes and other conditions.